Source comparison
CJC-1295 Combined with Other Peptides: Comparison Table
CJC-1295 + GHRP-2 GHRH receptor + ghrelin receptor (GHS-R1a) GH optimization, muscle hypertrophy, fat oxidation 3.2–4.1× baseline (synergistic) Both compounds within same 15-min window, 1–3× daily for GHRP-2 Gold standard for GH pulsatility; highest amplitude
This comparison does not assign a generated winner or score.
- CJC-1295 + GHRP-2
- GHRH receptor + ghrelin receptor (GHS-R1a)
- GH optimization, muscle hypertrophy, fat oxidation
- 3.2–4.1× baseline (synergistic)
- Both compounds within same 15-min window, 1–3× daily for GHRP-2
- Gold standard for GH pulsatility; highest amplitude response, minimal side effects when dosed correctly
- CJC-1295 + Ipamorelin
- GHRH receptor + selective GHS-R1a
- Sleep quality, insulin sensitivity, lean mass retention
- 2.8–3.5× baseline (synergistic)
- Both within same 15-min window, 2–3× daily for Ipamorelin
- Best option for cortisol-sensitive protocols; lower peak GH but cleaner hormonal profile
- CJC-1295 + GHRP-6
- Appetite stimulation research, caloric surplus studies
- 3.0–3.8× baseline (synergistic)
- Both within same 15-min window, 1–3× daily for GHRP-6
- Effective but appetite stimulation limits use; not ideal for fat loss protocols
- CJC-1295 + BPC-157 + TB-500
- GHRH receptor + VEGF upregulation + actin polymerization
- Tendon/ligament repair, angiogenesis, wound healing
- 2.1× baseline (CJC only—others non-GH pathways)
- CJC weekly; BPC-157 + TB-500 daily or twice daily
- Best tissue repair stack; no receptor conflict, complementary healing pathways
- CJC-1295 + MK-677
- GHRH receptor + ghrelin receptor agonist (oral)
- Oral GH secretagogue research, extended protocols
- 2.5–3.2× baseline (partial synergy)
- CJC weekly; MK-677 daily oral dosing
- Redundant ghrelin pathway activation—use one or the other, not both simultaneously